Intersect ENT (XENT) reported preliminary revenue of $22.4 to $22.8 million for Q3 2020, driven by increased demand for sinus surgery procedures. SINUVA achieved its highest quarterly revenue of approximately $1.7 million. The company holds around $130 million in cash and marketable securities. They expect Q4 2020 revenue to be 85% to 90% of Q4 2019 levels, positioning for growth in 2021. The recent acquisition of Fiagon AG aims to enhance product offerings and expand their market presence, despite ongoing pandemic challenges.
Intersect ENT, Inc. (Nasdaq: XENT) will release its third quarter 2020 financial results on November 2, 2020, at approximately 7:00 a.m. ET. A conference call will follow at 8:30 a.m. ET, accessible via the company's website or by phone. Intersect ENT focuses on innovative therapies for ear, nose, and throat conditions, particularly through their steroid-releasing implants. The company is committed to expanding its product portfolio and improving patient access to effective and less invasive treatments.
Intersect ENT (Nasdaq: XENT) has successfully completed its acquisition of Fiagon AG Medical Technologies for €60 million in cash. The deal involves an initial payment of €15 million and additional annual payments of €15 million for the next three years. This acquisition is expected to enhance Intersect's portfolio, allowing it to offer advanced surgical navigation solutions and better serve the growing ENT market. The strategic move aims to diversify Intersect's offerings, transitioning it from a single-technology company to a comprehensive solutions provider in the ENT field.